Abstract: The disclosure provides monoamine neurotransmitter releaser and/or monoamine uptake inhibitor compounds having biogenic amine transporter activity but lacking substantial activity at 5-HT2 receptor subtypes. The phenethylamine or vinylogous phenethylamine compounds of the disclosure are useful in treating diseases, conditions and/or disorders mediated by activity of one or more of the monoamine neurotransmitters.

Abstract: The disclosure provides monoamine neurotransmitter releaser and/or monoamine uptake inhibitor compounds having biogenic amine transporter activity but lacking substantial activity at 5-HT2 receptor subtypes. The phenethylamine or vinylogous phenethylamine compounds of the disclosure are useful in treating diseases, conditions and/or disorders mediated by activity of one or more of the monoamine neurotransmitters.

Abstract: Provided herein are compounds and prodrugs and methods of preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or more monoamine neurotransmitters, including dopamine, serotonin, and norepinephrine. Also provided are pharmaceutical compositions comprising one or more of these compounds or prodrugs, which may further comprise one or more additional therapeutic agents. Also provided are methods of treatment of various conditions that may be responsive to modification of monoamine neurotransmitter levels, such as pre-obesity, obesity, addiction, and depression.

Abstract: This invention relates, e.g., to methods for detecting a eubacterium, determining if the eubacterium is Gram-positive or Gram-negative, and determining the species of the eubacterium in a sample.

Abstract: This invention relates, e.g., to methods for detecting a aubacterium, determining if the eubacterium is Gram-positive or Gram-negative, and determining the species of the eubacterium in a sample.

Abstract: Provided herein are compounds and prodrugs and methods of preparation of compounds and prodrugs that are capable of functioning as releasers and/or uptake inhibitors of one or more monoamine neurotransmitters, including dopamine, serotonin, and norepinephrine. Also provided are pharmaceutical compositions comprising one or more of these compounds or prodrugs, which may further comprise one or more additional therapeutic agents. Also provided are methods of treatment of various conditions that may be responsive to modification of monoamine neutrotransmitter levels, such as pre-obesity, obesity, addiction, and depression.

Abstract: A stabilization element for implantation in a patient includes: a spring element including a plurality of helical coils terminating at first and second ends; and at least one sleeve including at least one bore sized and shaped to slide or thread onto the helical coils of the spring element, the at least one sleeve being operable to engage a tulip of a bone anchor.

Abstract: A skeletal fixation apparatus includes: a plate having first and second spaced apart surfaces and a plurality of apertures extending through the surfaces of the plate, each aperture for receiving a respective fixation element for coupling the plate to one or more bones of a patient; and at least one retention element having an elongate member coupled to the plate at first and second ends thereof, wherein the first end of the elongate member is fixed in position and the second end of the elongate member is operable to rotate about the first end such that: (i) at least a portion of the elongate member overlies at least a portion of a first of the apertures when the second end is in at least one first rotational position to retain a first fixation element in the first aperture, and (ii) the elongate member does not substantially overlie the first aperture when the second end is in at least one second rotational position to permit the first fixation element to enter or exit the first aperture.

Abstract: An intervertebral stabilizer includes: a first plate member operable to engage an endplate of a first vertebral bone of a spine; a second plate member spaced apart from the first plate member and operable to engage an endplate of an adjacent second vertebral bone of the spine; a ball element depending from the first plate member; and a socket element depending from the second plate member, wherein at least one of the ball and socket elements include one or more keyed surfaces such that: (i) an assembly function is obtained in which the ball element may at least one of be received into, and removed from, the socket element in one or more first articulation positions of the first and second plate members; and (ii) a capture function is obtained in which the ball element may at least one of not be received into, and not be removed from, the socket element in one or more second articulation positions of the first and second plate members.

Abstract: A stabilization rod for implantation in a patient, comprising: an elongate body including first and second ends; a flexible section disposed between the first and second ends, and including a first bore within the body and at least one through cut extending helically about the first bore to form a spring; and first and second fastening zones located at the first and second ends, respectively, and each operable to couple to a bone anchor.

Abstract: A cervical intervertebral stabilizer for a cervical region of a spine includes: a first surface operable to engage an endplate of a first vertebral bone of a spine; a second surface spaced apart from the first surface and operable to engage an endplate of an adjacent second vertebral bone of the spine; a spring element including at least one of: (i) a helical wound spring; and (ii) a hollow body having at least one slit forming a plurality of annular circumferential helical coils, the spring element being disposed between the first and second surfaces and being operable to provide reactive force in response to compression loads from the first and second vertebral bones, wherein at least some diameters of respective turns of the helical coils differ.

Abstract: An intervertebral stabilizer includes: a first surface operable to engage an endplate of a first vertebral bone of a spine; a second surface spaced apart from the first surface and operable to engage an endplate of an adjacent second vertebral bone of the spine; a spring element between the first and second surfaces and operable to provide reactive force in response to compression loads from the first and second vertebral bones, wherein a cross-sectional profile taken through the surfaces is hourglass shaped.

Abstract: An intervertebral stabilizer includes: a first surface operable to engage an endplate of a first vertebral bone of a spine; a second surface spaced apart from the first surface and operable to engage an endplate of an adjacent second vertebral bone of the spine; a spring element between the first and second surfaces and operable to provide reactive force in response to compression loads from the first and second vertebral bones, wherein a cross-sectional profile taken through the surfaces is hourglass shaped.

Abstract: A lumbar intervertebral stabilizer for a lumbar region of a spine includes: a first surface operable to engage an endplate of a first vertebral bone of a spine; a second surface spaced apart from the first surface and operable to engage an endplate of an adjacent second vertebral bone of the spine; a spring element including at least one of: (i) a helical wound spring; and (ii) a hollow body having at least one slit forming a plurality of annular circumferential helical coils, the spring element being disposed between the first and second surfaces and being operable to provide reactive force in response to compression loads from the first and second vertebral bones, wherein at least some diameters of respective turns of the helical coils differ.

Abstract: The present invention provides a compound having the structure: ##STR1## wherein X, Y, and Z are independently H, Cl, Br, F, OCH.sub.3, I, or an alkyl group having 1 to 6 carbon atoms; and R is ##STR2## wherein n is 0 to 6, X' and Y' are independently H, Cl, F, CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, C.sub.4 H.sub.9, OCH.sub.3, OH, CF.sub.3, OCF.sub.3, NO.sub.2, NH.sub.2, N(CH.sub.3).sub.2, NHCOCH.sub.3, NCS, NHCOCH.sub.2 Br, or N.sub.3, and (CH.sub.2).sub.n, if present, may be substituted with OH, OCH.sub.3, or an alkyl or alkenyl group having 1 to 3 carbon atoms. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier. The present invention further provides a method for treating a disease characterized by a dopamine deficiency which comprises administering to a subject in need of such treatment an amount of the pharmaceutical composition above effective to treat the disease.

Abstract: The present invention provides a compound having the structure: ##STR1## wherein X, Y, and Z are independently H, Cl, Br, F, OCH.sub.3, I, or an alkyl group having 1 to 6 carbon atoms; and R is ##STR2## wherein n is 0 to 6, X' and Y' are independently H, Cl, F, CH.sub.3, C.sub.2 H.sub.5, C.sub.3 H.sub.7, C.sub.4 H.sub.9, OCH.sub.3, OH, CF.sub.3, OCF.sub.3, NO.sub.2, NH.sub.2, N(CH.sub.3).sub.2, NHCOCH.sub.3, NCS, NHCOCH.sub.2 Br, or N.sub.3, and (CH.sub.2).sub.n, if present, may be substituted with OH, OCH.sub.3, or an alkyl or alkenyl group having 1 to 3 carbon atoms. The present invention also provides a pharmaceutical composition comprising the compound above and a pharmaceutically acceptable carrier. The present invention further provides a method for treating a disease characterized by a dopamine deficiency which comprises administering to a subject in need of such treatment an amount of the pharmaceutical composition above effective to treat the disease.